Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Lee

Cornea and External Diseases Specialist Atlanta, GA Medical Doctor

NPI 1366406787 CMS profile 152779

3225 Cumberland Blvd Se Ste 900, Suite 900, Atlanta, GA 30339

Open in the dashboard

General payments

$501,327

1,014 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$43,918 paid to institutions, not to them · program years 2022–2025

Through program year 2025, William Lee of Atlanta, GA is reported in the CMS Open Payments database as having received $501,327 across 1,014 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $43,918 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $88,077 156
2024 General $43,660 135
2023 General $80,190 145
2022 General $81,900 168
2021 General $70,498 162
2020 General $46,842 96
2019 General $90,160 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Lee
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to William Lee were reported at $88,077. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year William Lee Cornea and External Diseases Specialist median Middle half National median
2019 $90,160 $276 $111–$734 $163
2020 $46,842 $146 $48–$330 $114
2021 $70,498 $254 $116–$566 $132
2022 $81,900 $251 $106–$729 $149
2023 $80,190 $344 $149–$759 $160
2024 $43,660 $366 $170–$927 $164
2025 $88,077 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $148,049 170 payments
  2. Sun Pharmaceutical Industries Inc. $108,693 155 payments
  3. Glaukos Corporation $42,918 127 payments
  4. Dompe US, Inc. $41,638 56 payments
  5. Eyevance Pharmaceuticals LLC $37,937 53 payments
  6. Oyster Point Pharma, Inc. $31,472 60 payments
  7. Novartis Pharmaceuticals Corporation $28,915 71 payments
  8. Shire North American Group Inc $17,582 26 payments
  9. Kala Pharmaceuticals, Inc. $12,917 34 payments
  10. TissueTech, Inc. $7,351 24 payments
  11. Other $23,856 238 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $133,175 30 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $121,370 37 payments
  3. Honoraria $98,075 43 payments
  4. Consulting Fee $67,563 48 payments
  5. Travel and Lodging $49,250 138 payments
  6. Food and Beverage $31,894 718 payments
Products named General payments · program years 2019–2025
  1. MIEBO $146,416 110 payments
  2. Cequa $108,505 151 payments
  3. XIIDRA Ophthalmology $67,779 40 payments
  4. XIIDRA Ophthalmology $39,326 89 payments
  5. TYRVAYA $29,523 52 payments
  6. OXERVATE Solution/ Drops $24,914 48 payments
  7. XIIDRA Opthalmics $17,582 26 payments
  8. XIIDRA Ophthalmology $16,441 16 payments
  9. Oxervate Ophthalmic Solution/Drops $14,846 6 payments
  10. Zerviate $13,817 15 payments
  11. Other $110,248 642 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

3,415

Median for Ophthalmology: 891

Drug cost

$1,681,224

Median for Ophthalmology: $68,233

Branded share of claims

26.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxervate Cenegermin-Bkbj Brand 31 $1,220,858
Restasis Cyclosporine Brand 112 $117,082
Xiidra Lifitegrast Brand 69 $78,011
Prednisolone Acetate Generic 943 $38,790
Cequa Cyclosporine Brand 42 $26,532
Miebo Perfluorohexyloctane/Pf Brand 28 $22,632
Cyclosporine Generic 32 $19,628
Lumigan Bimatoprost Brand 31 $18,114
Prolensa Bromfenac Sodium Brand 51 $17,850
Combigan Brimonidine Tartrate/Timolol Brand 46 $12,317

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$357,922

Medicare's payments for the services billed

Medicare patients

995

Average age 75

Services billed

2,636

594 women, 401 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Ischemic heart disease 28%
Diabetes 23%
Chronic kidney disease 22%
Cancer 17%
Osteoporosis 17%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MIEBO
$13,489 28 —
XIIDRA
$13,441 69 —
XDEMVY
$2,590 — —
OXERVATE
$295 31 —
TYRVAYA
$102 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

1,014 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record